Taken together, our RNA and protein analyses suggest that ROR2 is preferentially expressed in HPV+ HNSCC and therefore may potentially serve as a target for HPV+ HNSCC-specific therapy. Here, ROR2 is linked to head and neck squamous cell carcinoma.